Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial

Background

Pre-exposure prophylaxis (PrEP) provides a strong preventative benefit to individuals at risk for HIV. While PrEP adherence is highly correlated with its efficacy, adherence rates are variable both across and within persons.

Objective

The objective of this study was to develop and pilot-test a smartphone-based intervention, known as mSMART, that targets PrEP adherence. mSMART provides contingency management in the form of monetary incentives for daily PrEP adherence based on a real-time adherence assessment using a camera-based medication event-monitoring tool as well as medication reminders, PrEP education, individualized behavioral strategies to address PrEP adherence barriers, and medication adherence feedback.

Methods

This was a 4-week open-label, phase I trial in a community sample of young men who have sex with men already on PrEP (N=10).

Results

Although adherence composite scores corresponding to PrEP biomarkers indicated that 90% (9/10) of the sample already had an acceptable baseline adherence in the protective range, by the end of the 4-week period, the scores improved for 30% (3/10) of the sample—adherence did not worsen for any participants. Participants reported mean PrEP adherence rates of 91% via daily entries in mSMART. At the end of the 4-week period, participants indicated acceptable ratings of satisfaction, usability, and willingness to recommend mSMART to others. There were no technical difficulties associated with smartphone compatibility, user misunderstandings about mSMART features that interfered with daily use, or study attrition.

Conclusions

This study is the first to apply contingency management to PrEP adherence. Findings indicated that mSMART is feasible and acceptable. Such an adherence intervention administered via a user-friendly smartphone app can allow for widespread dissemination. Future efficacy trials are needed.

Trial Registration

ClinicalTrials.gov NCT02895893; https://clinicaltrials.gov/ct2/show/NCT02895893 (Accessed by Webcite at http://www.webcitation.org/72JskjDJq)

An epidemic of acute haemorrhagic conjunctivitis caused by coxsackie A24 variant

An epidemic of acute haemorrhagic conjunctivitis (AHC) caused by a variant of coxsackie A24 (cox A24) occurred in Delhi during August to September 1988. Cox A24 antigen was detected by indirect immunofluorescence (IFA) in conjunctival cell smears of 13 of the 38 (34.2%) patients studied. Virus was isolated from conjunctival swabs in 11 (28.9%) patients and all isolates were neutralized by cox A24 antiserum. Five virus strains sent to Virology Division of Centres for Disease Control, Atlanta, USA, were confirmed as cox A24 variant. Enterovirus type 70 (EV70) was not demonstrable either by IFA or neutralization tests. Conjunctival swabs from 10 healthy laboratory controls did not show any evidence of EV70 or cox A24 virus or their antigens.

Trichomonal vaginitis: evaluation of serological tests and identification of immunoreactive surface peptides

An indirect haemagglutination assay (IHA) with polysaccharide and protein antigens of Trichomonas vaginalis and an enzyme linked immunosorbent assay (ELISA) were used to test for antibodies against T vaginalis in 58 women with trichonomal vaginitis and 48 with non-specific vaginitis. Eleven antibody positive sera were used in a radioimmunoprecipitation assay (RIPA) to identify surface peptides that elicited antibody responses in infected women. The serological tests were less sensitive than biological tests (smear examination and culture); antibodies were detected in 22 of the 58 women with trichomonal vaginitis by IHA using polysaccharide as antigen, in 27 by IHA using protein antigen, and in 36 by ELISA. The ELISA was also found to be of low specificity. Only two of the 11 sera tested by RIPA showed positive reactions with surface antigens, which were confirmed by autoradiography.